Oncolytics Biotech
ONCY
45 hedge funds and large institutions have $1.69M invested in Oncolytics Biotech in 2021 Q4 according to their latest regulatory filings, with 12 funds opening new positions, 11 increasing their positions, 4 reducing their positions, and 4 closing their positions.
200% more first-time investments, than exits
New positions opened: 12 | Existing positions closed: 4
175% more repeat investments, than reductions
Existing positions increased: 11 | Existing positions reduced: 4
22% more funds holding
Funds holding: 37 → 45 (+8)
0.29% more ownership
Funds ownership: 1.91% → 2.2% (+0.29%)
39% less capital invested
Capital invested by funds: $2.79M → $1.69M (-$1.1M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
ARC
Advisor Resource Council
Dallas,
Texas
|
+$185K |
| 2 |
Citadel Advisors
Miami,
Florida
|
+$145K |
| 3 |
TSS
Two Sigma Securities
New York
|
+$50.1K |
| 4 |
Renaissance Technologies
New York
|
+$47.3K |
| 5 |
Bank of Montreal
Toronto,
Ontario, Canada
|
+$36.9K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
JP Morgan Chase
New York
|
-$206K |
| 2 |
UBS Group
Zurich,
Switzerland
|
-$43.4K |
| 3 |
Bank of America
Charlotte,
North Carolina
|
-$22.5K |
| 4 |
CCM
Chiron Capital Management
Tallahassee,
Florida
|
-$21K |
| 5 |
CGA
Crescent Grove Advisors
Lake Forest,
Illinois
|
-$21K |
ONCY Hedge Fund Activity: Q4 2021 in Review
45 of the 6,519 institutional investors tracked by Wall St. Rank reported a position in Oncolytics Biotech (ONCY) for Q4 2021, worth a combined $1.69M — down 39% from $2.79M a quarter earlier.
Buyers outnumbered sellers: 12 funds opened new ONCY positions and 4 closed out — a net gain of 8 holders — while 11 added to existing stakes and 4 trimmed.
The largest buyer was Advisor Resource Council, opening a new position worth an estimated $185K. The largest seller was JP Morgan Chase, cutting an estimated $206K.
- 45 institutional investors held Oncolytics Biotech (ONCY) as of Q4 2021, up from 37 in Q3 2021.
- Funds reported $1.69M of Oncolytics Biotech stock for Q4 2021, down 39% quarter-over-quarter.
- 12 funds opened new Oncolytics Biotech positions in Q4 2021 and 4 closed out, a net change of +8 holders.
- The largest Oncolytics Biotech buyer in Q4 2021 was Advisor Resource Council, an estimated $185K added.
- The largest Oncolytics Biotech seller in Q4 2021 was JP Morgan Chase, an estimated $206K sold.
Based on aggregated 13F filings for Q4 2021.